Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AXNX

AXNX - Axonics Modulation Technologies Inc Stock Price, Fair Value and News

68.00USD+0.03 (+0.04%)Market Closed

Market Summary

AXNX
USD68.00+0.03
Market Closed
0.04%

AXNX Stock Price

View Fullscreen

AXNX RSI Chart

AXNX Valuation

Market Cap

3.5B

Price/Earnings (Trailing)

-217.74

Price/Sales (Trailing)

8.96

EV/EBITDA

-3.1K

Price/Free Cashflow

-213.02

AXNX Price/Sales (Trailing)

AXNX Profitability

EBT Margin

-3.60%

Return on Equity

-2.54%

Return on Assets

-2.23%

Free Cashflow Yield

-0.47%

AXNX Fundamentals

AXNX Revenue

Revenue (TTM)

387.1M

Rev. Growth (Yr)

29.38%

Rev. Growth (Qtr)

-16.7%

AXNX Earnings

Earnings (TTM)

-15.9M

Earnings Growth (Yr)

-106.66%

Earnings Growth (Qtr)

-389.88%

Breaking Down AXNX Revenue

Last 7 days

0.5%

Last 30 days

1.1%

Last 90 days

1.5%

Trailing 12 Months

33.5%

How does AXNX drawdown profile look like?

AXNX Financial Health

Current Ratio

9.96

Debt/Equity

1e-4

Debt/Cashflow

-117.65

AXNX Investor Care

Shares Dilution (1Y)

1.26%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024387.1M000
2023295.9M319.8M342.6M366.4M
2022194.3M217.4M240.9M273.7M
2021119.6M150.3M161.9M180.3M
202039.0M52.8M86.7M111.5M
20192.0M3.3M4.4M13.8M
20180369.7K538.3K707.0K
2017000201.0K
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Axonics Modulation Technologies Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 31, 2024
keese kari leigh
sold
-236,331
67.7359
-3,489
chief financial officer
Jan 31, 2024
woock john
sold
-1,076,930
67.7359
-15,899
evp, chief mktg/strtgy officer
Jan 31, 2024
cohen raymond w
sold
-2,381,660
67.7359
-35,161
chief executive officer
Jan 31, 2024
ford alfred j jr
acquired
-
-
25,500
chief commercial officer
Jan 31, 2024
noblett karen
sold
-764,603
67.7359
-11,288
chief medical officer
Jan 31, 2024
sama rinda
acquired
-
-
28,000
chief operating officer
Jan 31, 2024
keese kari leigh
acquired
-
-
6,167
chief financial officer
Jan 31, 2024
noblett karen
acquired
-
-
27,500
chief medical officer
Jan 31, 2024
woock john
acquired
-
-
28,000
evp, chief mktg/strtgy officer
Jan 31, 2024
ford alfred j jr
sold
-1,125,430
67.7359
-16,615
chief commercial officer

1–10 of 50

Which funds bought or sold AXNX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
Diversified Trust Co
sold off
-100
-527,068
-
-%
Jul 16, 2024
OAK RIDGE INVESTMENTS LLC
reduced
-2.87
-362,884
6,460,870
0.62%
Jul 15, 2024
Granite Bay Wealth Management, LLC
new
-
1,698,000
1,698,000
0.02%
Jul 12, 2024
SG Americas Securities, LLC
added
379
439,000
559,000
-%
Jul 12, 2024
INSPIRION WEALTH ADVISORS, LLC
unchanged
-
-5,220
201,690
0.03%
Jul 12, 2024
QRG CAPITAL MANAGEMENT, INC.
added
20.02
140,790
969,120
0.01%
Jul 12, 2024
Opal Wealth Advisors, LLC
new
-
18,489
18,489
0.01%
Jul 10, 2024
ALBION FINANCIAL GROUP /UT
unchanged
-
-78.00
3,026
-%
Jul 10, 2024
NBC SECURITIES, INC.
reduced
-0.15
-1,000
45,000
-%
Jul 10, 2024
CWM, LLC
added
62.5
8,000
22,000
-%

1–10 of 45

Are Funds Buying or Selling AXNX?

Are funds buying AXNX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXNX
No. of Funds

Unveiling Axonics Modulation Technologies Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
10.38%
5,260,830
SC 13G/A
Feb 12, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 25, 2024
blackrock inc.
8.3%
4,189,817
SC 13G/A
Dec 11, 2023
fmr llc
-
0
SC 13G/A
Mar 10, 2023
vanguard group inc
10.28%
5,092,888
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.82%
4,863,283
SC 13G/A
Jan 31, 2023
blackrock inc.
7.3%
3,630,843
SC 13G/A
Jun 06, 2022
cooperatieve gilde healthcare iv u.a.
0%
0
SC 13G/A

Recent SEC filings of Axonics Modulation Technologies Inc

View All Filings
Date Filed Form Type Document
Apr 30, 2024
8-K
Current Report
Apr 30, 2024
10-Q
Quarterly Report
Apr 29, 2024
10-K/A
Annual Report

Peers (Alternatives to Axonics Modulation Technologies Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
182.2B
40.3B
1.20% -2.11%
32.36
4.52
-2.84% -3.00%
67.6B
19.7B
0.55% -8.69%
50.74
3.43
4.82% -17.56%
18.9B
3.9B
2.12% -30.48%
40.81
4.82
5.72% 46.72%
18.2B
14.9B
5.25% -24.14%
6.87
1.22
2.98% 207.68%
MID-CAP
9.6B
3.5B
-1.00% 21.66%
30.68
2.71
6.16% 35.06%
9.1B
12.4B
7.63% -10.11%
23.5
0.73
-0.93% -18.83%
9.1B
2.6B
7.84% -17.07%
-28.21
3.49
-6.25% -68.58%
5.7B
3.9B
7.40% -32.03%
-59.88
1.45
0.23% 90.80%
3.5B
387.1M
1.13% 33.46%
-217.74
8.96
30.82% 65.57%
2.3B
6.6B
15.49% -18.17%
12.46
0.35
1.50% -10.09%
SMALL-CAP
1.5B
3.2B
-0.18% -22.08%
-2.15
0.46
7.94% -1695.32%
426.3M
169.3M
10.73% 14.84%
-5.55
2.52
7.49% -244.90%
296.4M
324.0M
25.64% -24.02%
-1.54
0.91
-3.19% -337.41%
47.8M
50.5M
-7.48% -77.96%
-2.1
0.95
14.25% -10.06%
6.1M
3.5M
-32.81% -89.76%
-0.5
1.73
-0.62% -1.48%

Axonics Modulation Technologies Inc News

Latest updates
Defense World24 hours ago
The Motley Fool6 months ago

Axonics Modulation Technologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-16.7%91,409,000109,735,00093,100,00092,894,00070,650,00085,918,00070,384,00068,980,00048,420,00053,135,00046,913,00045,869,00034,373,00034,783,00035,243,00015,213,00026,296,0009,946,0001,309,0001,488,0001,077,000
Gross Profit-16.3%69,253,00082,760,00069,104,00070,190,00052,500,00062,967,00051,260,00050,196,00033,242,00035,391,00031,194,00028,734,00020,399,00022,131,00021,809,0006,750,00016,401,0005,408,000677,000716,000529,000
Operating Expenses8.2%88,432,00081,694,00069,791,00082,260,00066,866,00066,576,00067,635,00071,625,00056,775,00053,071,00047,696,00044,744,00042,015,00033,012,00030,578,00026,155,00031,106,00028,071,00025,724,00019,986,00014,148,000
  S&GA Expenses2.0%56,191,00055,094,00047,544,00044,270,00042,654,00043,824,00039,751,00039,381,00033,063,00031,338,00028,112,00025,411,00020,928,00018,284,00017,057,00014,220,00016,569,00016,301,00015,707,00010,750,0005,914,000
  R&D Expenses13.8%11,056,0009,714,0008,167,0008,949,0008,056,0008,103,0007,936,0007,135,00011,236,00010,182,0008,648,0009,098,0009,369,0008,111,0007,719,0006,370,0006,855,0006,118,0004,855,0004,874,0004,219,000
EBITDA Margin-125.5%0.000.01-0.01-0.07-0.13-0.18-0.28-0.32-0.34-0.38-0.39-0.39---------
Interest Expenses-100.0%-14,00016,00039,000----1,000-1,0002,007,000170,000253,000256,000264,000329,000339,000367,000370,000360,000
Income Taxes444.1%3,847,000-1,118,000-427,000-304,000-807,000-522,000-520,000-465,000-1,111,000-2,487,000528,0003,296,000-555,000---1,000--1,000-
Earnings Before Taxes-379.8%-15,265,0005,456,0003,501,000-7,646,000-10,055,000143,000-16,772,000-21,908,000-23,779,000-17,653,000-16,722,000-21,852,000-23,058,000-11,348,000-9,168,000-19,783,000-14,615,000-22,751,000-25,006,000-19,060,000-13,117,000
EBT Margin-51.0%-0.04-0.02-0.04-0.11-0.16-0.23-0.33-0.37-0.41-0.44-0.45-0.44---------
Net Income-389.9%-19,112,0006,593,0003,928,000-7,342,000-9,248,000665,000-16,252,000-21,443,000-22,668,000-15,166,500-17,250,000-25,148,000-22,503,000-11,348,000-9,168,000-19,783,000-14,616,000-22,751,000-25,006,000-19,061,000-13,117,000
Net Income Margin-148.5%-0.04-0.02-0.04-0.10-0.16-0.22-0.31-0.35-0.41-0.44-0.47-0.45---------
Free Cashflow-384.4%-12,295,0004,323,00011,151,000-19,465,000-1,575,0009,018,0002,884,000-1,476,000-9,458,000-7,860,000-3,678,000-12,323,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.6%716720661649666659632514526548561566445342348349217220126146159
  Current Assets-1.9%482491475455470465449313307321330332228328334336204212118138153
    Cash Equivalents122.0%23310514714524023924120321322122923113124126928816017176.0083.0089.00
  Inventory16.6%93.0080.0075.0070.0066.0056.0058.0058.0062.0065.0070.0070.0071.0063.0044.0030.0019.0016.0013.008.005.00
  Net PPE---7.006.007.007.007.007.007.007.006.006.006.006.006.006.005.003.003.003.003.00
  Goodwill-0.9%99.0099.0095.0099.0097.0094.0087.0095.0010310611010787.00--------
Liabilities7.4%88.0082.0050.0048.0089.0089.0083.0076.0062.0066.0071.0061.0011555.0054.0051.0045.0037.0034.0032.0028.00
  Current Liabilities5.6%48.0046.0036.0032.0066.0065.0061.0030.0026.0027.0028.0024.0024.0046.0039.0031.0020.0012.0016.0011.007.00
  Long Term Debt------------0.0075.00-6.0011.0016.0020.0014.0016.0018.00
    LT Debt, Current-----------0.000.000.0021.0015.0010.005.00-6.004.002.00
    LT Debt, Non Current------------0.0075.00-6.0011.0016.0020.0014.0016.0018.00
Shareholder's Equity-1.6%62763861160157757055043846348249050433028729429817218392.00114131
  Retained Earnings-5.0%-399-380-386-390-383-374-374-358-337-314-299-282-257-234-223-213-194-179-156-131-112
  Additional Paid-In Capital0.9%1,0441,0341,0221,010982970961821812804796788590522518513367363250247245
Shares Outstanding0.5%51.0051.0051.0050.0049.0050.0047.0045.0045.0043.0042.0041.00---------
Float----2,500---2,647---2,893---1,136---633-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-264.0%-9,2365,63012,344-19,209-7819,3533,847-842-9,167-6,776-2,994-11,953-25,583-28,314-19,146-12,975-23,307-28,136-23,904-18,359-13,055
  Share Based Compensation-14.3%9,55111,14811,47011,20410,7148,7578,2187,9057,1386,8446,6906,3275,3033,5823,7753,8163,9222,9212,7821,8751,142
Cashflow From Investing464.5%138,232-37,922-11,053-68,623694-10,030-99,401-10,632-291-1,084-684-370-140,864-1,023-648-55311,87812,34217,45611,4404,049
Cashflow From Financing-57.1%248578878-6,7661,930161131,8834801,4442021,523112,57356,2151,0551,296141,495344110,49211130844.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AXNX Income Statement

2024-03-31
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]  
Net revenue$ 91,409$ 70,650
Cost of goods sold22,15618,150
Gross profit69,25352,500
Operating expenses  
Research and development11,0568,056
General and administrative15,10412,168
Sales and marketing56,19142,654
Amortization of intangible assets2,2542,222
Acquisition-related costs3,8271,766
Total operating expenses88,43266,866
Loss from operations(19,179)(14,366)
Other income (expense)  
Interest and other income3,9733,628
Interest and other expense(59)683
Other income, net3,9144,311
Loss before income tax expense (benefit)(15,265)(10,055)
Income tax expense (benefit)3,847(807)
Net loss(19,112)(9,248)
Foreign currency translation adjustment(1,152)3,071
Comprehensive loss$ (20,264)$ (6,177)
Net loss per share, basic (in USD per share)$ (0.38)$ (0.19)
Net loss per share, diluted (in USD per share)$ (0.38)$ (0.19)
Weighted-average shares used to compute basic net loss per share (in shares)50,928,17148,579,084
Weighted-average shares used to compute diluted net loss per share (in shares)50,928,17148,579,084

AXNX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 232,645$ 104,811
Short-term investments100,161240,149
Accounts receivable, net of allowance for credit losses of $1,079 and $442 at March 31, 2024 and December 31, 2023, respectively50,52957,243
Inventory, net93,18779,940
Prepaid expenses and other current assets5,5089,279
Total current assets482,030491,422
Restricted cash15,82612,714
Property and equipment, net17,03710,760
Intangible assets, net78,42281,375
Other assets23,70324,235
Goodwill98,54399,417
Total assets715,561719,923
Current liabilities  
Accounts payable15,77018,452
Accrued liabilities14,75210,527
Accrued compensation and benefits16,40915,060
Operating lease liabilities, current portion1,4561,777
Total current liabilities48,38745,816
Operating lease liabilities, net of current portion30,15425,840
Deferred tax liabilities, net9,92110,703
Total liabilities88,46282,359
Commitments and contingencies (Note 3)
Stockholders’ equity  
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, par value $0.0001, 75,000,000 shares authorized at March 31, 2024 and December 31, 2023; 51,018,179 and 50,770,520 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively55
Additional paid-in capital1,043,5771,033,778
Accumulated deficit(399,464)(380,352)
Accumulated other comprehensive loss(17,019)(15,867)
Total stockholders’ equity627,099637,564
Total liabilities and stockholders’ equity$ 715,561$ 719,923
AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
 CEO
 WEBSITEaxonics.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES610

Axonics Modulation Technologies Inc Frequently Asked Questions


What is the ticker symbol for Axonics Modulation Technologies Inc? What does AXNX stand for in stocks?

AXNX is the stock ticker symbol of Axonics Modulation Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axonics Modulation Technologies Inc (AXNX)?

As of Wed Jul 17 2024, market cap of Axonics Modulation Technologies Inc is 3.47 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart for subscribers.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart for subscribers. The fair value of Axonics Modulation Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axonics Modulation Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axonics Modulation Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether AXNX is over valued or under valued. Whether Axonics Modulation Technologies Inc is cheap or expensive depends on the assumptions which impact Axonics Modulation Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXNX.

What is Axonics Modulation Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jul 17 2024, AXNX's PE ratio (Price to Earnings) is -217.87 and Price to Sales (PS) ratio is 8.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXNX PE ratio will change depending on the future growth rate expectations of investors.